BioCentury
ARTICLE | Top Story

Forest, Nabriva in antibiotic deal

June 2, 2012 12:16 AM UTC

Forest Laboratories Inc. (NYSE:FRX) and Nabriva Therapeutics AG (Vienna, Austria) partnered to develop the Austrian biotech's pleuromutilin antibiotic BC-3781. As part of the deal, Forest will have the exclusive right to acquire Nabriva for the next 12 months. Nabriva will receive $25 million. Forest will also fund and help develop BC-3781 during the period. Citi and WilmerHale advised Nabriva. Details were not disclosed. ...